Macular Edema | Medical XPRT
News
-
Bayer initiates phase III study to investigate aflibercept 8 mg in retinal vein occlusion
Global phase III QUASAR study will assess the efficacy and safety of aflibercept 8 mg in macular edema secondary to retinal vein occlusion (RVO) Study comes after positive data from the phase III PULSAR trial in neovascular (wet) age-related ...
Bayer submits aflibercept 8 mg for regulatory approval in two major retinal eye diseases in the EU
Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical’s Proprietary Suprachoroidal Space Platform
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million
Equipment & Solutions
-
Showcase
Triamcinolone Acetonide Injectable Suspension
FIRST commercial product developed by Clearside; FIRST approved therapeutic delivered into the suprachoroidal space; FIRST therapy for macular edema associated with uveitis; FIRST uveitis trial using visual acuity change as a primary endpoint (Phase 3 PEACHTREE).